What is the recommended maintenance dose of bevacizumab (Avastin) for ovarian cancer?

Maintenance Dose of Bevacizumab in Ovarian Cancer

For newly diagnosed advanced ovarian cancer (stage III-IV), the recommended maintenance dose of bevacizumab is 15 mg/kg intravenously every 3 weeks, continued as a single agent for up to 22 cycles total (approximately 15 months) or until disease progression, whichever occurs first. 1

Dosing Regimens Based on Clinical Setting

First-Line Treatment (Newly Diagnosed Stage III-IV Disease)

The FDA-approved and guideline-supported approach involves two validated regimens:

GOG-218 Regimen (Preferred):

• Bevacizumab 15 mg/kg IV every 3 weeks starting with cycle 2 of chemotherapy
• Continue with carboplatin/paclitaxel for 6 cycles
• Maintenance: Bevacizumab 15 mg/kg every 3 weeks as single agent for up to 22 total cycles 1, 2

ICON-7 Regimen (Alternative):

• Bevacizumab 7.5 mg/kg IV every 3 weeks starting with cycle 1 of chemotherapy
• Continue with carboplatin/paclitaxel for 5-6 cycles
• Maintenance: Bevacizumab 7.5 mg/kg every 3 weeks for up to 12 additional cycles 3, 2

The most recent ESMO-ESGO consensus (2019) provides the strongest recommendation: bevacizumab at either 15 mg/kg or 7.5 mg/kg every 3 weeks for a maximum of 15 months improves progression-free survival in stage III-IV ovarian cancer (Level I evidence, Grade A recommendation, 97.5% consensus). 4

Recurrent Disease Dosing

Platinum-Resistant:

• 10 mg/kg IV every 2 weeks with weekly chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
• OR 15 mg/kg IV every 3 weeks with 3-weekly topotecan 1

Platinum-Sensitive:

• 15 mg/kg IV every 3 weeks with carboplatin/paclitaxel or carboplatin/gemcitabine for 6-10 cycles
• Maintenance: Continue bevacizumab 15 mg/kg every 3 weeks as single agent until progression 1, 5

Duration of Maintenance Therapy

The critical distinction between regimens lies in total treatment duration:

• GOG-218 protocol: Up to 22 cycles total (approximately 15 months) 6
• ICON-7 protocol: Up to 18 cycles total (approximately 12 months) 6
• EMA approval: Maximum 15 months or until progression 6

Real-world evidence suggests that patients receiving ≥10 doses during first-line treatment experience superior outcomes compared to those receiving 3-9 doses, with median real-world progression-free survival of 17.3 months. 7

Key Clinical Considerations

Patient Selection: While bevacizumab improves progression-free survival across all risk groups, the 2013 ESMO guidelines specifically recommend prioritizing bevacizumab for high-risk patients (stage IV or suboptimal debulking with residual disease >1 cm), as this subgroup demonstrated overall survival benefit in ICON-7 exploratory analyses. 6 However, the 2019 ESMO-ESGO consensus broadened this to all stage III-IV patients. 4

Surgical Timing: When used in the neoadjuvant setting, bevacizumab must be stopped 4-6 weeks before interval debulking surgery and restarted at least 4-6 weeks (preferably 6-7 weeks) after surgery to minimize wound healing complications. 4

Common Pitfalls:

• Do not reduce bevacizumab dose for toxicity; instead, withhold or discontinue per protocol 1
• Hypertension (most common toxicity) should be managed medically; withhold bevacizumab only if severe and uncontrolled 4
• Gastrointestinal perforation risk is approximately 1-3%; avoid in patients with inflammatory bowel disease or recent large bowel resection 4
• Proteinuria ≥2 grams/24 hours requires withholding bevacizumab until <2 grams/24 hours 1

Integration with PARP Inhibitors: The PAOLA-1 trial demonstrated that combining olaparib maintenance with bevacizumab (15 mg/kg every 3 weeks for up to 15 months) provides superior outcomes in HRD-positive tumors, with median PFS2 of 36.5 months versus 32.6 months with bevacizumab alone. 8 Current evidence suggests reserving bevacizumab for first-line use when PARP inhibitors are planned, as sequential use maximizes benefit. 9

The NCCN 2016 guidelines classify bevacizumab-containing regimens as Category 2B, reflecting panel disagreement about routine use due to modest survival benefits, toxicity risks, and cost considerations (estimated $167,771 per life-year saved in high-risk patients). 2, 10 However, the 2019 ESMO-ESGO consensus provides stronger support with Grade A recommendation. 4